Semaglutide (Wegovy ... In part 1 of the so-called ESSENCE trial, treatment with the GLP-1 receptor agonist resulted in higher week-72 rates of steatohepatitis resolution without worsening ...

Novo Nordisk’s latest attempt in weight loss, a combination drug called CagriSema, matched the bar set by Lilly’s currently ...

Already established as cornerstone therapies in diabetes and obesity, GLP-1 receptor agonists have now cracked into the ...

Key Takeaways Novo Nordisk's U.S.-listed shares tumbled over 19% Friday morning after it released data from a new weight loss ...

Novo Nordisk’s (NVO) next-gen weight loss therapy, CagriSema, caused up to ~23% of weight loss compared to ~16% of weight ...

The 26-week PIONEER 5 trial is one of 10 clinical trials for oral semaglutide that are due to complete this year. Novo's oral semaglutide on target in phase 3 trial | pharmaphorum Skip to main content ...

Novo Nordisk’s hopes of getting semaglutide approved for obesity management may have received a boost, with a new, large trial showing the drug was able to cut body weight significantly over the ...

The most common adverse events reported with both treatments were mild to moderate gastrointestinal-related side effects.

Tirzepatide showed superior weight loss efficacy over semaglutide in a phase 3b trial, achieving primary and secondary endpoints. Tirzepatide is the only FDA-approved dual GIP and GLP-1 receptor ...

Tirzepatide treatment led to a 47% greater relative reduction in weight compared with semaglutide. Topline results were announced from a phase 3b clinical trial comparing tirzepatide with ...